Next-Generation Psychedelic Drug Development
Abstract Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.
Authors
- Mark M. Rasenick (ORCID: https://orcid.org/0000-0003-2405-4364)
- Matthew W. Johnson (ORCID: https://orcid.org/0000-0001-7068-0513)
- Lindsay P. Cameron (ORCID: https://orcid.org/0000-0002-8420-7898)
- Charles D. Nichols (ORCID: https://orcid.org/0000-0002-0615-0646)
- Kevin S. Murnane (ORCID: https://orcid.org/0000-0002-8143-0541)
Institutions
- Illinois College (US)
- Louisiana State University in Shreveport (US)
- Sheppard and Enoch Pratt Hospital (US)
- Jesse Brown VA Medical Center (US)
- AXON Neuroscience (Slovakia) (SK)
- Louisiana State University Health Sciences Center New Orleans (US)
- Louisiana State University Health Sciences Center Shreveport (US)
- Stanford University (US)
Publication Details
- Journal
- ACS Chemical Neuroscience
- Published
- 2026-09-15
- DOI
- https://doi.org/10.1021/acschemneuro.6c00492
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00